NEWARK, Calif., Jan. 4, 2022 /PRNewswire/ -- Protagonist
Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company")
today announced that Dinesh V.
Patel, Ph.D., President and Chief Executive Officer, will
present virtually at the 40th Annual J.P. Morgan Healthcare
Conference on Tuesday, January 11 at
2:15 a.m. EST.
Dr. Patel will also participate in a fireside chat at the H.C.
Wainwright BioConnect 2022 Conference taking place virtually during
January 10-13, 2022.
A live and archived webcast of the events will be available in
the Investors section of the Protagonist Therapeutics website at
https://investors.protagonist-inc.com/. The fireside chat at H.C.
Wainwright BioConnect will be available on January 10, 2022.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with
multiple peptide-based new chemical entities (NCEs) in different
stages of clinical development, all derived from the Company's
proprietary technology platform.
Protagonist's pipeline includes rusfertide (PTG-300), an
investigational, injectable hepcidin mimetic currently in a Phase 2
proof-of-concept clinical trial for polycythemia vera (PV), a Phase
2 study in PV subjects with high hematocrit levels, and a recently
completed Phase 2a study for hereditary hemochromatosis. The
Company plans to initiate a single, global Phase 3 randomized,
placebo-controlled trial evaluating the efficacy and safety of a
once weekly, subcutaneously self-administered dose of
rusfertide.
The Company is also evaluating an orally delivered,
gut-restricted alpha-4-beta-7 integrin specific antagonist peptide
(PN-943) currently in a Phase 2 study in adults with moderate to
severe active ulcerative colitis (UC). The Company is targeting
ulcerative colitis as the initial indication.
The Company has a worldwide license and collaboration agreement
with Janssen Biotech, Inc., for the development of oral peptide
IL-23 receptor antagonist PN-235, a second-generation oral
interleukin-23 receptor antagonist candidate. Under the
collaboration with Janssen, PN-235 is expected to advance into
Phase 2 studies in psoriasis and new Phase 2 clinical studies in
inflammatory bowel diseases.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-301453047.html
SOURCE Protagonist Therapeutics, Inc.